206 related articles for article (PubMed ID: 35776183)
1. Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.
Hertz DL; Douglas JA; Miller RM; Kidwell KM; Gersch CL; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM
Support Care Cancer; 2022 Oct; 30(10):8059-8067. PubMed ID: 35776183
[TBL] [Abstract][Full Text] [Related]
2. Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.
Liang Y; Gersch CL; Lehman J; Henry NL; Smith KL; Rae JM; Stearns V; Hertz DL
Pharmacogenet Genomics; 2024 Jun; 34(4):126-129. PubMed ID: 38359166
[TBL] [Abstract][Full Text] [Related]
3. Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer.
Hertz DL; Smith KL; Zong Y; Gersch CL; Pesch AM; Lehman J; Blackford AL; Henry NL; Kidwell KM; Rae JM; Stearns V
Front Genet; 2021; 12():662734. PubMed ID: 34211496
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.
Hertz DL; Douglas JA; Kidwell KM; Gersch CL; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM
Pharmacogenet Genomics; 2021 Jul; 31(5):116-123. PubMed ID: 34096894
[TBL] [Abstract][Full Text] [Related]
5. Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Roberts KE; Rickett K; Feng S; Vagenas D; Woodward NE
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012988. PubMed ID: 31994181
[TBL] [Abstract][Full Text] [Related]
6. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
Santa-Maria CA; Bardia A; Blackford AL; Snyder C; Connolly RM; Fetting JH; Hayes DF; Jeter SC; Miller RS; Nguyen A; Quinlan K; Rosner GL; Slater S; Storniolo AM; Wolff AC; Zorzi J; Henry NL; Stearns V
Breast Cancer Res Treat; 2018 Aug; 171(1):121-129. PubMed ID: 29752687
[TBL] [Abstract][Full Text] [Related]
7. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Roberts KE; Adsett IT; Rickett K; Conroy SM; Chatfield MD; Woodward NE
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013167. PubMed ID: 35005781
[TBL] [Abstract][Full Text] [Related]
8. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Henry NL; Azzouz F; Desta Z; Li L; Nguyen AT; Lemler S; Hayden J; Tarpinian K; Yakim E; Flockhart DA; Stearns V; Hayes DF; Storniolo AM
J Clin Oncol; 2012 Mar; 30(9):936-42. PubMed ID: 22331951
[TBL] [Abstract][Full Text] [Related]
9. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
Kamdem LK; Xi J; Clark BL; Gregory BJ; Kidwell KM; Storniolo AM; Stearns V; Hayes DF; Gersch CL; Rae JM; Henry NL; Hertz DL
Breast Cancer Res Treat; 2019 Jun; 175(2):297-303. PubMed ID: 30747308
[TBL] [Abstract][Full Text] [Related]
10. Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
Henry NL; Skaar TC; Dantzer J; Li L; Kidwell K; Gersch C; Nguyen AT; Rae JM; Desta Z; Oesterreich S; Philips S; Carpenter JS; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
Breast Cancer Res Treat; 2013 Apr; 138(3):807-16. PubMed ID: 23546553
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
12. Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
Hack CC; Häberle L; Brucker SY; Janni W; Volz B; Loehberg CR; Hartkopf AD; Walter CB; Baake G; Fridman A; Malter W; Wuerstlein R; Harbeck N; Hoffmann O; Kuemmel S; Martin B; Thomssen C; Graf H; Wolf C; Lux MP; Bayer CM; Rauh C; Almstedt K; Gass P; Heindl F; Brodkorb T; Willer L; Lindner C; Kolberg HC; Krabisch P; Weigel M; Steinfeld-Birg D; Kohls A; Brucker C; Schulz V; Fischer G; Pelzer V; Rack B; Beckmann MW; Fehm T; Rody A; Maass N; Hein A; Fasching PA; Nabieva N
Breast; 2020 Apr; 50():11-18. PubMed ID: 31958661
[TBL] [Abstract][Full Text] [Related]
13. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Borrie AE; Rose FA; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Teft WA; Kim RB
Breast Cancer Res Treat; 2020 Sep; 183(2):365-372. PubMed ID: 32632513
[TBL] [Abstract][Full Text] [Related]
14. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
[TBL] [Abstract][Full Text] [Related]
15. Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
Roberts K; Rickett K; Greer R; Woodward N
Crit Rev Oncol Hematol; 2017 Mar; 111():66-80. PubMed ID: 28259297
[TBL] [Abstract][Full Text] [Related]
16. A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS): Results from ECOG-ACRIN E1Z11.
Stearns V; Jegede OA; Chang VT; Skaar TC; Berenberg JL; Nand R; Shafqat A; Jacobs NL; Luginbuhl W; Gilman P; Benson AB; Goodman JR; Buchschacher GL; Henry NL; Loprinzi CL; Flynn PJ; Mitchell EP; Fisch MJ; Sparano JA; Wagner LI
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38640040
[TBL] [Abstract][Full Text] [Related]
17. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kalaivani S; Devi J; Damodaran SE; Pradhan SC; Dubashi B; Dkhar SA; Adithan C
Breast Cancer Res Treat; 2020 Jul; 182(1):147-158. PubMed ID: 32385792
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.
Kadakia KC; Snyder CF; Kidwell KM; Seewald NJ; Flockhart DA; Skaar TC; Desta Z; Rae JM; Otte JL; Carpenter JS; Storniolo AM; Hayes DF; Stearns V; Henry NL
Oncologist; 2016 May; 21(5):539-46. PubMed ID: 27009936
[TBL] [Abstract][Full Text] [Related]
19. Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancer.
Joyce E; Tao X; Stearns V; Hayes DF; Storniolo AM; Kidwell KM; Henry NL
Breast Cancer Res Treat; 2024 Apr; 204(3):539-546. PubMed ID: 38198070
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
Kidwell KM; Harte SE; Hayes DF; Storniolo AM; Carpenter J; Flockhart DA; Stearns V; Clauw DJ; Williams DA; Henry NL
Cancer; 2014 Aug; 120(16):2403-11. PubMed ID: 24802413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
